The executive of a private health group has expressed disappointment that a planned inquiry into South Africa’s private healthcare market by the Competition Commission will not also umbrella the pharmaceutical sector. Netcare CEO Richard Friedland offered the remarks on Monday, noting that consumers pay “40 percent more” for drugs in South Africa. The Commission’s planned review of the healthcare market will bring private hospitals and medical schemes under a close watch but appears to let the pharmaceutical sector off the hook under the argument that pharmaceutical prices are already regulated. Further, Friedland said the allowance of parallel imports of drugs could help lower costs for consumers. Netcare is currently the nation’s third-largest private hospital group.
Featured News
Former DOJ Antitrust Lawyer Returns to Sullivan & Cromwell
Jul 27, 2026 by
CPI
Trip.com Accepts $765 Million Antitrust Penalty as China Concludes Monopoly Investigation
Jul 27, 2026 by
CPI
Google Seeks to Exclude EU DMA Decision From Evidence in UK Shopping Damages Trial
Jul 27, 2026 by
CPI
Judge Allows Beef Price-Fixing Class Action to Move Toward Trial
Jul 27, 2026 by
CPI
Japanese Banks Combine Ship Finance Operations to Form $12.8B Maritime Lending Platform
Jul 27, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes